Synthesis of oncological [¹¹C]radiopharmaceuticals for clinical PET

详细信息	查看全文 | 推荐本文 |

• 作者：Filippo Lodi^a ; ^{filippo.lodi@aosp.bo.it} ; Claudio Malizia^a ; Paolo Castellucci^c ; Gianfranco Cicoria^b ; Stefano Fanti^c ; Stefano Boschi^a
• 关键词：Clinical PET ; Oncology ; [11C]radiopharmaceuticals ; Radiosynthesis ; [11C]choline ; [11C]methionine ; [11C]acetate
• 刊名：Nuclear Medicine and Biology
• 出版年：2012
• 期刊代码：43_09698051
• 类别：ph
• 出版时间：May, 2012
• 卷：39
• 期：4
• 页码：447-460
• 文件大小：1448 K

摘要

Positron emission tomography (PET) is a nuclear medicine modality which provides quantitative images of biological processes in vivo at the molecular level. Several PET radiopharmaceuticals labeled with short-lived isotopes such as ¹⁸F and ¹¹C were developed in order to trace specific cellular and molecular pathways with the aim of enhancing clinical applications. Among these [¹¹C]radiopharmaceuticals are N-[¹¹C]methyl-choline ([¹¹C]choline), l-(S-methyl-[¹¹C])methionine ([¹¹C]methionine) and 1-[¹¹C]acetate ([¹¹C]acetate), which have gained an important role in oncology where the application of 2-[¹⁸F]fluoro-2-deoxy-d-glucose ([¹⁸F]FDG) is suboptimal. Nevertheless, the production of these radiopharmaceuticals did not reach the same level of standardization as for [¹⁸F]FDG synthesis. This review describes the most recent developments in the synthesis of the above-mentioned [¹¹C]radiopharmaceuticals aiming to increase the availability and hence the use of [¹¹C]choline, [¹¹C]methionine and [¹¹C]acetate in clinical practice.